About Endocyte (NASDAQ:ECYT)
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-14.52
Forward P/E Ratio-19.11
Sales & Book Value
Price / Sales14,416.29
Price / CashN/A
Book Value$1.99 per share
Price / Book7.30
EPS (Most Recent Fiscal Year)($1.00)
Return on Equity-34.20%
Return on Assets-32.76%
Endocyte (NASDAQ:ECYT) Frequently Asked Questions
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
How were Endocyte's earnings last quarter?
Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative return on equity of 34.20% and a negative net margin of 70,510.81%. View Endocyte's Earnings History.
What price target have analysts set for ECYT?
4 analysts have issued twelve-month target prices for Endocyte's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endocyte's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.
Who are some of Endocyte's key competitors?
Some companies that are related to Endocyte include Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA) and Clovis Oncology (CLVS).
Who are Endocyte's key executives?
Endocyte's management team includes the folowing people:
- Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
- Mr. Michael T. Andriole, Chief Financial Officer (Age 45)
- Ms. Katherine K. Parker, VP of HR (Age 53)
- Dr. Alison A. Armour, Chief Medical Officer (Age 54)
- Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52)
Has Endocyte been receiving favorable news coverage?
News stories about ECYT stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Endocyte earned a media sentiment score of 0.03 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Endocyte's major shareholders?
Endocyte's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (8.19%), VHCP Management II LLC (6.19%), BlackRock Inc. (2.48%), Rock Springs Capital Management LP (0.97%), Eventide Asset Management LLC (0.50%) and Millennium Management LLC (0.27%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.
Which major investors are selling Endocyte stock?
ECYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Barclays PLC. Company insiders that have sold Endocyte company stock in the last year include Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.
Which major investors are buying Endocyte stock?
ECYT stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, VHCP Management II LLC, Rock Springs Capital Management LP, BlackRock Inc., Eventide Asset Management LLC, Tibra Equities Europe Ltd, Baird Financial Group Inc. and Element Capital Management LLC. View Insider Buying and Selling for Endocyte.
How do I buy shares of Endocyte?
Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endocyte's stock price today?
One share of ECYT stock can currently be purchased for approximately $14.52.
How big of a company is Endocyte?
Endocyte has a market capitalization of $998.04 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.
How can I contact Endocyte?
Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.
MarketBeat Community Rating for Endocyte (ECYT)MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.